Dr. Barry Ticho, Chief Medical Officer, Stoke Therapeutics, a clinical-stage company focused on RNA-based medicines and Co-Founder & former Board Member of Verve Therapeutics. Dr. Ticho formerly held roles across industry, which include: Head of Development (CV/Metabolic) at Moderna, Head of External R&D Innovation (CVRM) at Pfizer and VP (Clinical Development) at Biogen. 

​

Dr. Jane Hughes, Formerly Chief Scientific Officer, Gyroscope Therapeutics, a leading gene therapy company acquired by Novartis in 2021. Dr. Hughes formerly held roles across industry at companies such as GlaxoSmithKline and MedImmune.

 

Professor Ole Kiehn, Karolinska Institute & University of Copenhagen. World leader in motor neurophysiology and circuits and recipient of The Brain Prize (2022). 

​

Professor Tom Otis, Chief Scientific Officer, Sainsbury Wellcome Centre for Neural Circuits, UCL. Formerly Vice Director & Section Head, Synapses and Circuits, Hoffman La Roche.  

​

Dr. Kimberly Ritola, Director – BRAIN Initiative Viral Vector Core, University of North Carolina, Chapel Hill. Dr Ritola is a world-leading expert in neural viral vector development. 

​

Professor Martyn Goulding, Salk Institute for Biological Studies. World leader in molecular genetic targeting of neural circuits and recipient of the Brain Prize (2022). 

​

Dr. Anna Dreismann, Senior Director of Biology, AGCT. Formerly Group Lead, Gyroscope Therapeutics, where Dr. Driesmann was employee number one since its founding and integral to R&D until its acquistion by Novartis.